Targeted Therapy for SLE—What Works, What Doesn’t, What’s Next

For many years, the failure of randomized controlled trials (RCTs) has prevented patients with systemic lupus erythematosus (SLE) from benefiting from biological drugs that have proved to be effective in other rheumatological diseases. Only two biologics are approved for SLE, however they can only b...

Descripción completa

Detalles Bibliográficos
Autores principales: Venturelli, Veronica, Isenberg, David Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179673/
https://www.ncbi.nlm.nih.gov/pubmed/37176637
http://dx.doi.org/10.3390/jcm12093198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179673/
https://www.ncbi.nlm.nih.gov/pubmed/37176637
http://dx.doi.org/10.3390/jcm12093198

Ejemplares similares